Sinclair Pharma is running high level training workshops for experienced HA injectors who are keen to advance to the next stage of their proficiency by treating with Ellansé collagen stimulating dermal filler.
Ellansé is unique amongst dermal fillers because it includes polycaprolactone beads in a carboxy cellulose gel matrix which has been developed for the induction of neocollagenesis. Polycaprolactone is a biocompatible and biodegradable substance safely used in surgical procedures for years. Ellansé acts as an immediate volumiser as well as a collagen stimulator as the polycaprolactone beads are resorbed by the skin. Studies by Dr Pierre Nicolau confirmed the presence of new collagen type I persisting 20 months after injection with Ellansé.1
The outcome with Ellansé is appreciated in two phases: an immediate correction of lines, wrinkles and volume restoration, along with progressive and long lasting results through natural collagen stimulation
Progressive clinicians will appreciate the advanced transformative results which can be achieved with Ellansé, which offers a unique combination of total and predictable bio-resorbability across the range. It also has an exemplary safety record and data about this will be shared at the event. Training will be delivered by a globally accredited Sinclair Pharma trainer throughout 2018 at Wigmore Medical in London.
- 15th January
- 28th February
- 12th March
- 8th May
- 18th June
- 2nd July
- 5th September
- 3rd October
- 23rd October
- 19th November
The day-long workshops will provide delegates with a solid foundation in the use of Ellansé to achieve full face rejuvenation. They will first observe a demonstration of the procedure carried out on a model by one of Sinclair’s expert trainers, which will showcase the latest and most effective techniques.
They will hen actively participate themselves as particular emphasis is placed on the practical nature of these sessions, which are delivered in small groups of four. On completion of the course delegates will be able to determine indications between the ideal and non-ideal patient; where to use needle vs cannula; manage postoperative care; and use Ellansé in conjunction with other aesthetic treatments.
1Nicolau PJ, Hofste, J.M.
Neocollagenessis after injection of a polycapnote based dermal filler.
Eu.J.Aes. Med and Derm 2013.3.19-26
Galadari H etal. Randomised split face study comparing polycaprolane to HA.
J.Cos Derm 2014 27-30.